Imugene Ltd · ASX:IMU
Imugene — Investor Presentation (July 2017)
40 slides from Imugene's investor presentation, July 2017
Slide 1: Mimotope Induced B-Cell Antibodies for Immuno-Oncology
ASX:IMU v MIMOTOPE INDUCED B-CELL ANTIBODIES FOR IMMUNO-ONCOLOGY Leslie Chong | Chief Executive Officer 2H/2017 -1-
Slide 2: Notice: Forward Looking Statements
NOTICE: FORWARD LOOKING STATEMENTS Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other fa
Slide 3: What Does Imugene Do?
WHAT DOES IMUGENE DO? Imugene’s technology can induce a patient’s body v to make its own specific antibodies that target cancer. -3-
Slide 4: Executive Summary
EXECUTIVE SUMMARY • Two novel oncology platforms: B cell mimotope vaccines and small molecule arginine modulator • Lead mimotope: HER-Vaxx Phase 1b/2 mimotope study in Her-2+ gastric cancer about to commence • POC demonstrated in Phase 1 Her-2+ breast cancer study – safety & immunogenecity establish
Slide 5: A Better Way to Make Antibodies to Treat Cancer?
A BETTER WAY TO MAKE ANTIBODIES TO TREAT CANCER? IN A FACILITY USING B CELLS IN YOUR OWN BODY B Cells are cells in the human VSv body that naturally produce millions of antibodies Teaching B cells to make antibodies For example, Roche’s Herceptin using peptide mimotopes -5-
Slide 6: Two Mimotope Peptide Programs and Commercial Opportunities
TWO MIMOTOPE PEPTIDE PROGRAMS AND COMMERCIAL OPPORTUNITIES • A mimotope is a small molecule, often a peptide, which mirrors the structure of an epitope, the specific target an Peptides identified antibody binds to. via computer aided • Because of this property, the mimotope induces an programs: HER-
Slide 7: Mimotope: Platform Technology
MIMOTOPE: PLATFORM TECHNOLOGY SELECTION OF MIMOTOPES CREATION OF A VACCINE IMMUNIZATION ENDOGENOUS AB PRODUCTION A library of mimotopes The selected mimotope or Immunization with the Successful delivery will result in can be interrogated with mimotopes can be used in peptide will lead to endogenous
Slide 8: Advantages of Mimotope Induced B-Cell Based Antibodies v. Synthetic Antibodies
ADVANTAGES OF MIMOTOPE INDUCED B-CELL BASED ANTIBODIES V. SYNTHETIC ANTIBODIES Issue Natural B Cell Derived Antibodies Monoclonal Antibodies Safety Stimulates the immune system to produce natural Synthetic Ab, with side effects (including ventricular Abs, potentially safer, as demonstrated by HER-Va
Slide 9: The Monoclonal Antibody (mAb) Market
THE MONOCLONAL ANTIBODY (mAb) MARKET • Multiple antibody therapies are approved to treat cancer, for example: Sales in 2016 - Herceptin: >US$6.7 billion - Perjeta: >US$1.8 billion - Rituxan: >US$7.3 billion - YERVOY®: >US$1.0 billion - OPDIVO®: >US$3.7 billion - KEYTRUDA: >US$1.4 billion v Total mon
Slide 10: HER-Vaxx Mimotope: Mechanism of Action
HER-Vaxx MIMOTOPE: MECHANISM OF ACTION Peptides “mimic” the HER-Vaxx epitope Antibody Secretion Tumor Cell 3 B-cell HER-2/neu EPITOPE = Peptides v Activation Antibody Via helper T- Binding Site cells B-Cell HER-Vaxx attacks the same target as the HER-Vaxx the world’s largest Immunotherapy selling br
Slide 11: HER-Vaxx Phase 1b/2 Mimotope Peptide Therapy for HER2+ Gastric Cancer
ASX:IMU v HER-VAXX IS A Phase 1b/2 STAGE MIMOTOPE PEPTIDE THERAPY BEING DEVELOPED FOR HER2+ GASTRIC CANCER - 11 -
Slide 12: Phase 1 in Breast Cancer, Completed at Medical University of Vienna
PHASE 1 IN BREAST CANCER, COMPLETED AT MEDICAL UNIVERSITY OF VIENNA- SINGLE AGENT, NO CHEMO DESIGN RESULTS CLINICAL ENDPOINTS • 10 patients • Patients developed anti-HER-2 antibodies 1 Safety and Tolerability • All late stage breast cancer • Induction of cytokines (Th1 biased; IFNγ) patients • Induc
Slide 13: HER-Vaxx Has Been Optimised Since Phase 1a Breast Cancer Study
Ph1b/2 HER-VAXX HAS BEEN OPTIMISED SINCE Formulation PHASE 1A BREAST CANCER STUDY 3rd Generation 2nd Generation • Changed the delivery system from virosomes to CRM197 • Incorporated the three B Cell (which gave CD4 T-Helper epitopes into a vsingle 49-mer response), and added a 1st Generation peptide
Slide 14: HER-Vaxx Inhibits HER-2 Expressing Cells
HER-VAXX INHIBITS HER-2 EXPRESSING CELLS • HER-Vaxx antibodies demonstrate anti-tumour effect by inhibiting HER-2+ gastric and breast cancer cell lines • Combination with Herceptin v shows significantly higher inhibition than Herceptin alone. HER-2+ gastric cancer cells* HER-2+ breast cancer cells *
Slide 15: Phase 1b/2, in Gastric Cancer
PHASE 1B/2, IN GASTRIC CANCER Phase 1b lead-in Phase 2 • Open label • Open label • ~Up to 18 patients in 3 cohorts of up to 6 pts per • ~68 patients from sites in Asia cohort • Combination with chemo • Combination with chemo/cisplatin • Randomized • Endpoints: • Primary Endpoints: - Recommended Phas
Slide 16: Gastric Market Opportunity
GASTRIC MARKET OPPORTUNITY • Asia is the largest market for gastric cancer globally • Gastric cancer is the second leading cause of cancer mortality in the world & its management, especially in advanced stages, has evolved Chemotherapy relatively little • ~20% patients with metastatic gastric cancer
Slide 17: Mimotope B-Cell Peptide Therapy
ASX:IMU v MIMOTOPE B-CELL PEPTIDE THERAPY - 17 -
Slide 18: Mimotope Proposed Development Path 2017-2018
MIMOTOPE PROPOSED DEVELOPMENT PATH 2017-2018 2H, 2018:Toxicology, 2H, 2018: GMP 2H, 2017 : 1H, 18:Formal pre- immunotox, safety Mimotope Candidate manufacturing clinical pharmacology (cont. dev of 2-3 1H, 2018: CMC additional candidate) manufacturing v Proposed Phase l Cohort 5 Expansions Assumption
Slide 19: Arginine Modulators
ASX:IMU v ARGININE MODULATORS - 19 -
Slide 20: Secondary Technology Platform: First-in-Class Small Molecule Arginine Modulators – A12
SECONDARY TECHNOLOGY PLATFORM FIRST-IN-CLASS SMALL MOLECULE ARGININE MODULATORS – A12 • Arginine is a critical amino acid for the health of cancer fighting T- cells and depletion of it limits the effectiveness of T-cells to fight tumors • IMU’s A12 molecule increase the availability of arginine in t
Slide 21: Arginine Proposed Development Path 2017-2018
ARGININE PROPOSED DEVELOPMENT PATH 2017-2018 Given that Arginine is a critical amino acid for the health of Syngeneic mouse models cancer fighting T-cells: Cell line Cancer Type • In vitro effect of lead compound on human PBMC’s will H22 Liver readout T-cell cytokine changes MC38 Colon • Flow cytome
Slide 22: A Team with Track Record in Drug Development
A TEAM WITH TRACK RECORD IN DRUG DEVELOPMENT Leslie Chong Prof Ursula Wiedermann Chief Executive Officer Chief Scientific Officer • Over 19 years of oncology experience in Phase I - III of • Co-inventor of Her-Vaxx; clinical program development • Professor of Vaccinology at Medical University of • L
Slide 23: Business Strategy and Partnering Opportunities
BUSINESS STRATEGY AND PARTNERING OPPORTUNITIES 2018 2018-2019 2018-2020 Phase 1b Big Pharma Phase 1b Mimotope + v and/or biotech? Gastric Study others - 23 -
Slide 24: Financial Summary
FINANCIAL SUMMARY ASX:IMU Top 5 shareholders (as at May. 2017) Market Cap No. of Shares % Capital $33.1M AUD, $25.7M USD (14/Jul/17) Platinum Asset Ordinary Shares 2.365 billion 240,227,753 10.16% Management 12 month price National Nominees 0.7 cents – 2.1 cents AUD 95,548,708 4.04% range Limited Av
Slide 25: 36 Month Targets and Investor Deliverables
36 MONTH TARGETS AND INVESTOR DELIVERABLES HER-VAXX MIMOTOPES ARGININE MODULATORS 3-4 mimotope candidates. Move at Definitive clinical least two mimotope Candidate selection data package from a Phase 1b and Phase 2 trial in gastric + candidatesvfrom pre- clinical to IND enabled + Develop at least on
Slide 26: Imugene Pipeline
IMUGENE PIPELINE MIMOTOPE IMMUNE ID OF PROGRAM PRE-IND WORK CLINICAL DEVELOPMENT IDENTIFICATION CHARACTERIZATION CANDIDATE HER-Vaxx HER-Vaxx /Her2 Combo *Mimotope #2 *Mimotope #3 v Her2 / *Mimotope Combo Combo #3? TBD DISCOVERY ID OF CANDIDATE PRE-IND WORK Arginine Modulator - 26 -
Slide 27: Executive Summary
EXECUTIVE SUMMARY • Two novel oncology platforms: B cell mimotope vaccines and small molecule arginine modulator • Lead mimotope: HER-Vaxx Phase 1b/2 mimotope study in Her-2+ gastric cancer about to commence • POC demonstrated in Phase 1 Her-2+ breast cancer study – safety & immunogenecity establish
Slide 28: Appendix
ASX:IMU APPENDIX v SR. TEAM MEMBER ON MARKETED ONCOLOGY DRUGS - 28 -
Slide 29: Herceptin (Trastuzumab) Mild Treatment Related Side Effects
HERCEPTIN ® (TRASTUZUMAB) MILD TREATMENT RELATED SIDE EFFECTS • Diarrhea • Redness or irritation at injection (IV) site • Muscle/joint/back pain • Stomach or abdominal pain v • Headache • Sleep problems (insomnia) • Nausea and vomiting (may be severe) • Weight loss - 29 -
Slide 30: Herceptin (Trastuzumab) Serious Treatment Related Side Effects
HERCEPTIN ® (TRASTUZUMAB) SERIOUS TREATMENT RELATED SIDE EFFECTS – BLACK BOX WARNING1 • CARDIOMYOPATHY: Herceptin can result in sub-clinical and clinical cardiac failure manifesting as CHF (congestive heart failure), and decreased LVEF ( left ventricular ejection fraction). • INFUSION REACTIONS: PUL
Slide 31: Phase 1a Study Design
PHASE IA STUDY DESIGN* ADMINISTRATION & READOUT SCHEDULE Patient inclusion criteria • Metastatic breast cancer • HER2 +, ++ • ER/PR pos. • Life expectance > 4 mo v Primary endpoint D0 D28 D56 D84 • Safety & Tolerability Secondary endpoint Vaccination with 10µg • Immunogenicity of each peptide antige
Slide 32: Patient Characteristics – Ages 55-84
PATIENT CHARACTERISTICS – AGES 55-84 * Patient ID Age Metastatic disease since Prior chemotherapy Current antihormonal therapy 1 55 Oct. 2006 no Anastrozol 2 66 May 2004 yes (1 adj) Fulvestrant 3 84 Mar. 1999 no Anastrozol 4 79 Sept. 2003 no Anastrozol 5 67 Apr. 2004 no Fulvestrant v 6 69 Sept. 2004
Slide 33: Safety and Tolerability – Few Grade 1 Local Reactions, None Systemic
SAFETY AND TOLERABILITY – FEW GRADE 1 LOCAL REACTIONS, NONE SYSTEMIC* Patient ID Local vaccination reaction grade Systemic grade 3/4 toxicity 1 1 no 2 0 no 3 0 no 4 1 no 5 1 v no 6 0 no 7 0 no 8 0 no 9 1 no 10 0 no * Breast Cancer Res Treat. 2010 Feb;119(3):673-83. - 33 -
Slide 34: Phase 1 Secondary Endpoint – Immunologic Responses
PHASE 1 SECONDARY ENDPOINT – IMMUNOLOGIC RESPONSES Western blot analysis demonstrating increase of Her-2/neu-specific IgG post- vaccination in patient: ANTIBODY (lane 1) Polyclonal rabbit anti Her-2/neu antibody was used as positive control RESPONSES (lane 2) serum of a healthy volunteer as negative
Slide 35: Phase 1 – Reduction in Regulatory T Cells
Cancer PatientsPhase vs. Healthy Controls I - Regulatory T cells: Cancer Patients vs. Healthy Controls REDUCTION IN REGULATORY T CELLS* p=0.033 pre-vaccination post-vaccination p=0.033 pre-vaccination post-vaccination CD4+Foxp3+ Data.026 CD4+Foxp3+ Data.026 10.0 p=0.007 p=0.007 10.0 1.06 8.32 1.06 8
Slide 36: Encouraging Immunogenicity, Even at Low Dose, in Patients Up to 84 Years
ENCOURAGING IMMUNOGENICITY, EVEN AT LOW DOSE, AND IN PATIENTS AGES UP TO 84 YEARS, WITH NO CARDIOTOXICITY Antibody and cellular responses in human Pat. # Peptide-specific ab P4, P6, P7 HER2- specific ab Infl. HIT IL-2, IFNγ, TNF T reg • Immunogenicity in 8/10 patients in Phase 1 study with 10 µg of
Slide 37: Tumor Growth Inhibition In Vivo
TUMOR GROWTH INHIBITION IN VIVO* Time to disease progression • Prolonged time to Cumulative proportion tumor-free Untreated Tentanus toxoid disease progression Peptide Peptide + IL12 • Immunization of c-neu transgenic mice IL12 (recognized HER2 cancer model) with tetanus toxoid-conjugated peptides P
Slide 38: Mimotope
MIMOTOPE Peptides “mimic” the epitope EPITOPE = Antibody Binding Site HER2+ Cancer v Cell Mimotope Anti HER-2 Peptides Patient’s B Cells Antibody make antibodies B-Cell against HER-2 HER-2 Receptor - 38 -
Slide 39: Phase 1b/2 Enhanced Gastric Formulation
PHASE 1B/2 ENHANCED GASTRIC FORMULATION Her-2/neu specific IgG kinetic, after last immunization 1.60 3 w. after 3 doses vacc. 1.40 1.20 8 w. after 3 doses vacc. 1.00 16 w. after 3 doses vacc. 0.80 6 mo. after 3 doses vacc. OD v 0.60 Pre-immunization 0.40 0.20 0.00 P467-CRM-Montanide (µg) In the mous
Slide 40: Leslie Chong
Leslie Chong Chief Executive Officer leslie.chong@imugene.com v +61 458 040 433 - 40 -